{"id":"drug-dorzolamide-timolol","safety":{"commonSideEffects":[{"rate":"approximately 25-30%","effect":"Ocular burning or stinging"},{"rate":"approximately 15-20%","effect":"Blurred vision"},{"rate":"approximately 10-15%","effect":"Bitter taste"},{"rate":"approximately 5-10%","effect":"Ocular allergic reactions"},{"rate":"approximately 5%","effect":"Headache"},{"rate":"rare to uncommon","effect":"Systemic beta-blocker effects (bradycardia, bronchospasm)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye by inhibiting the enzyme carbonic anhydrase II. Timolol is a non-selective beta-adrenergic antagonist that reduces aqueous humor production and may increase uveoscleral outflow. Together, these complementary mechanisms provide additive intraocular pressure reduction.","oneSentence":"Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:31.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT06177678","phase":"PHASE2","title":"A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Kukje Pharma","startDate":"2024-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT05083689","phase":"PHASE2, PHASE3","title":"Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-10-06","conditions":"Diabetic Macular Edema","enrollment":62},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT03034772","phase":"PHASE2, PHASE3","title":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-02-08","conditions":"Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":52},{"nctId":"NCT02571972","phase":"PHASE2","title":"Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2015-02-01","conditions":"Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema","enrollment":14},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00811850","phase":"PHASE4","title":"Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma","enrollment":15},{"nctId":"NCT02967614","phase":"PHASE1","title":"KJ-TFC-004 Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Kukje Pharma","startDate":"2016-12","conditions":"Glaucoma, Eye Diseases, Ocular Hypertension","enrollment":32},{"nctId":"NCT00824824","phase":"NA","title":"Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2009-01","conditions":"Glaucoma","enrollment":21},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT01471158","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Glaucoma","enrollment":120},{"nctId":"NCT00314171","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":437},{"nctId":"NCT00333125","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":319},{"nctId":"NCT00869141","phase":"PHASE4","title":"Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-03","conditions":"Glaucoma","enrollment":52},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT00108017","phase":"PHASE3","title":"Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":330},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00972257","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-01","conditions":"Glaucoma","enrollment":64},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01145898","phase":"","title":"Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data","status":"COMPLETED","sponsor":"Indiana University","startDate":"2010-06","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT01284166","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00822081","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2005-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Drug: dorzolamide/timolol","genericName":"Drug: dorzolamide/timolol","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure. Used for Elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}